Pulmonx Corporation reported a narrowed net loss and improved gross margin for the second quarter of 2026, sending its stock up over 38%. Revenue fell 5% to $22.8 million, with U.S. revenue down 4% to $14.2 million and international revenue down 6% to $8.6 million, though international sales excluding China grew 12%. Gross margin rose to 78% from 72% a year earlier, while net loss shrank to $10.1 million, or $0.24 per share, from $15.2 million, or $0.38 per share. The company reaffirmed full-year 2026 revenue guidance of $90 million to $92 million and expects gross margin of approximately 76%.
Pulmonx CorpNarrowed net loss and improved gross margin, with reaffirmed guidance, driving stock up 38%.